Author details

Full Name

Michael Murphy

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37292995	Antigen spacing on protein nanoparticles influences antibody responses to vaccination.		2023
36347257	Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.	Cell Host Microbe	2023
38096058	Antigen spacing on protein nanoparticles influences antibody responses to vaccination.		2023
36888664	Improving the secretion of designed protein assemblies through negative design of cryptic transmembrane domains.	Proc Natl Acad Sci U S A	2023
37013198	Process development of a SARS-CoV-2 nanoparticle vaccine.		2023
37321165	Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.	Cell Host Microbe	2023
36943870	Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines.		2023
35319882	Generation of Potent and Stable GLP-1 Analogues Via "Serine Ligation".	ACS Chem Biol	2022
35383176	Structure-based design of stabilized recombinant influenza neuraminidase tetramers.	Nat Commun	2022
36206752	Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens.	Cell Reports Medicine	2022
36263073	CD8<sup>+</sup> T cell clonotypes from prior SARS-CoV-2 infection predominate during the cellular immune response to mRNA vaccination.	Res Sq	2022
35606518	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.	NPJ Vaccines	2022
35977542	Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses.	Immunity	2022
34545368	Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants.	bioRxiv	2021
34267764	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.	Front Immunol	2021
33873199	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.	Nature	2021
33762730	Quadrivalent influenza nanoparticle vaccines induce broad protection.	Nature	2021
33594366	Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.	bioRxiv	2021
34518698	De novo design of tyrosine and serine kinase-driven protein switches.	Nat Struct Mol Biol	2021
34665783	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination.	JCI Insight	2021
33160446	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.	Cell	2020
32384820	Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.	Viruses	2020
32873791	Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak.	Nature Communications	2020
11294672	Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus.	Journal of Infectious Diseases	2001